



A guide for surveillance of antimicrobial resistance in leprosy

2017 update

A guide for surveillance of antimicrobial resistance in leprosy

2017 update



A guide for surveillance of antimicrobial resistance in leprosy: 2017 update

ISBN: 978 92 9022 619 2

© World Health Organization 2017

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; <https://creativecommons.org/licenses/by-nc-sa/3.0/igo>).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: "This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition".

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization..

Suggested citation. A guide for surveillance of antimicrobial resistance in leprosy: 2017 update. New Delhi: World Health Organization, Regional Office for South-East Asia; 2017. Licence: CC BY-NC-SA 3.0 IGO.

Cataloguing-in-Publication (CIP) data. CIP data are available at <http://apps.who.int/iris>.

Sales, rights and licensing. To purchase WHO publications, see <http://apps.who.int/bookorders>. To submit requests for commercial use and queries on rights and licensing, see <http://www.who.int/about/licensing>.

Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

General disclaimers. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

Cover photos: Mr Masanori Matsuoka



List of contributors	iv
Abbreviations and acronyms	v
Executive summary	vii
1. Objectives of the guide and its target population.....	1
2. Background	2
3. Rationale for developing the guide.....	3
4. Global Leprosy Strategy 2016–2020 at a glance	4
5. Overview of the surveillance system on antimicrobial resistance in leprosy	5
5.1 Objectives	5
5.2 Definitions	5
5.3 Resistance among new cases.....	6
5.4 Resistance among retreatment cases.....	7
5.5 Scheme for surveillance of AMR in leprosy.....	8
6. Setting up or expanding a surveillance system at the national level	9
6.1 Selection of the testing laboratories involved	9
6.2 Selection of laboratories for quality control purposes	10
6.3 Identification of sample collection health facilities	11
6.4 Calculation of sample size	12
6.5 Systematic collection of samples.....	12
6.6 Laboratory tests.....	14
6.7 Systematic recording of information	19
6.8 Monitoring antimicrobial resistance.....	19
Bibliography	21

Annexes

1. International reference laboratories.....	24
2. National leprosy drug resistance register	25
3. Form 1. Clinical report form for MB leprosy cases to be tested for drug resistance	26
4. Form 2. Report of the testing laboratory	28
5. Reporting form for treatment outcomes of resistant cases	31
6. Laboratory protocols.....	32
7. Sentinel surveillance protocol.....	41
8. Clinical management of resistant cases detected.....	44



List of contributors

This Guide was prepared by Professor Emmanuelle Cambau, Université Paris Diderot, France; Dr Laura Gillini (Global Leprosy Programme); and Mr Masanori Matsuoka, National Leprosy Museum of Jukanbo, Japan.

Other contributors were:

Dr Bertrand Cauchoix, Fondation Raoul Follereau, Paris, France

Professor Stewart Cole, Ecole Polytechnique Fédérale de Lausanne, Switzerland

Dr Erwin Cooreman, Global Leprosy Programme, WHO Regional Office for South-East Asia, New Delhi, India

Dr Anil Kumar, National Leprosy Eradication Programme (NLEP), New Delhi, India

Dr V R R Pemmaraju, Global Leprosy Programme, WHO Regional Office for South-East Asia, New Delhi, India

Dr Rupali Roy, National Leprosy Eradication Programme (NLEP), New Delhi, India

Dr Paul Saunderson, American Leprosy Missions, Norway

Dr David Scollard, National Hansen Disease Program, Baton Rouge, USA

Dr Sirenda Vong, Health Emergency Information and Risk Assessment Department, WHO Regional Office for South-East Asia, New Delhi, India

Professor Aditama Tjandra Yoga, Special Adviser to the Regional Director, WHO Regional Office for South-East Asia, New Delhi, India

Mr Rakesh Mani Rastogi, Health Systems Development, WHO Regional Office for South-East Asia, New Delhi, India

The final draft of the document was reviewed after a workshop held in Hyderabad, India from 10 to 11 August 2017 to discuss a model of antimicrobial resistance in leprosy in India. This workshop was attended by NLEP staff, including state and district leprosy coordinators, WHO staff, experts from the Jalma Institute of Leprosy & Other Mycobacterial Diseases (Agra), the Foundation for Medical Research (Mumbai), staff from dermatology departments of tertiary-level hospitals and representatives of NGOs (The Leprosy Mission, Netherlands Leprosy Relief, Lepira UK, American Leprosy Missions), and took into account challenges and approaches discussed with the country representatives.

Abbreviations and acronyms



AMR	antimicrobial resistance
BI	bacillary index
DRDR	dapsone resistance-determining region
GLASS	Global Antimicrobial Resistance Surveillance System
GLP	Global Leprosy Programme
IATA	International Air Transport Association
ILEP	International Federation of Anti-Leprosy Associations
MB	multibacillary
MDT	multidrug therapy
MoU	memorandum of understanding
NGO	nongovernmental organization
PB	paucibacillary
PBS	phosphate buffered saline
PCR	polymerase chain reaction
QRDR	quinolone resistance-determining region
RLEP	<i>M. leprae</i> -specific repetitive element
RRDR	rifampicin resistance-determining region
TB	tuberculosis
WHO	World Health Organization



预览已结束，完整报告链接

<https://www.yunbaogao.cn/report/index/re>

